RKLB Falls Another 21% as Neutron Delay Widens the Gap to Consensus

Rocket Lab has extended its losses sharply, dropping another 21% this week to $50.90, compounding a month in which the stock has shed roughly the same amount and leaving it trading at less than half the analyst consensus target.

The selloff has pushed the spread between price and Street expectations to an uncomfortable extreme. The consensus mean target is $102.15, implying roughly 100% upside from current levels. That gap is not a bullish signal so much as a measure of how far the stock has fallen away from where analysts set their models. This week brought a fresh round of cuts: Citizens trimmed its target from $130 to $90 on October 16 while keeping its Market Outperform rating, and Keybanc cut from $135 to $100 on October 15, also maintaining Overweight. Cantor Fitzgerald and TD Cowen held their existing targets of $122 and $90 respectively. Every active rating remains at Buy or equivalent. No analyst has downgraded to Hold or Sell. The consistency of direction is notable, but the persistence of target cuts, from $130 to $90 at Citizens in one move, reflects a Street that is repricing the Neutron delay in real time. The bear case is blunt: the inaugural Neutron launch has slipped into 2027 after defects were found in a first-stage tank component, trimming modelled FY27 revenue from $1,299M to $1,186M with further FY28 pressure implied. The bull case rests on Space Systems already contributing over 66% of total revenue, 100% mission success across 97 Electron launches, and large contract awards including the $515M SDA Tranche 2 and the pending $805M SDA Tranche 3 opportunity.

Short positioning has picked up alongside the price decline, though the picture is one of steady accumulation rather than a crowded or aggressive short. Short interest has climbed to 9.1% of free float, up 8.5% over the week and 5.6% over the month, with the absolute share count rising from around 44.8 million to 48.6 million across October. That is a meaningful build, but borrow conditions tell a less pressured story. The cost to borrow has actually eased, falling 14% over the week to 0.38%, its lowest level in the 30-day window. Availability remains loose at 227%, meaning more than two shares are available to borrow for every one already shorted. The lending market is not signalling a crowded short or any squeeze dynamics. Options positioning has edged more defensive, with the put/call ratio at 0.79, slightly above its 20-day average of 0.74 and at a z-score of 1.4. That is above-average caution but not at an extreme. The 52-week high PCR is 0.85, so there is room for hedging demand to intensify further before reaching last year's peak.

The peer group has also sold off hard this week, which provides some context for the move. FLY fell 11%, LUNR dropped 13.5%, and SATL lost 19% over the same period. RKLB at minus 21% sits toward the weaker end of the cohort, suggesting company-specific pressure from the Neutron news layered on top of a broad sector decline. Retail attention has spiked sharply, with the ORTEX Wikipedia-views signal hitting a z-score of 2.25 against the stock's own 90-day history, the highest attention reading in recent months. That kind of elevated visibility often accompanies both capitulation selling and opportunistic buying interest.

One index mechanics story is worth flagging separately. ORTEX puts the probability of RKLB being deleted from the Nasdaq-100 at the December 2026 Annual Review at 27%. The stock needs to close below $46.08 to trigger the exit line under the index's market-cap band rules. At $50.90, it sits only 9.5% above that threshold. Daily volatility is running at 4.2%, so the margin is not wide. If deletion were confirmed, ORTEX estimates passive tracker selling of approximately $2.7 billion, equivalent to 2.7 days of normal trading volume. In past Nasdaq-100 deletions, 79% of the 19 comparable cases moved in the expected direction between announcement and effective date, with a median move of minus 3.5%. The announcement date is projected for December 11, with an effective date of December 21, though all dates are ORTEX estimates at this stage.

The next scheduled earnings release is November 9. The prior print, in August, produced a one-day drop of 3.4% before recovering most of that ground over five days. With the stock now down more than 40% from where it was when those results landed, the question heading into November is less about quarterly execution and more about whether management provides any revision to the Neutron timeline that changes the 2027 revenue trajectory the Street is currently repricing.